Companies: 10,795·Total market cap: $144.5T
CEL-SCI Corporation

CEL-SCI Corporation

CVMAMEXHealthcare● Active
$1.38
+$0.01(+0.73%)
Market Cap$9482790
P/E Ratio
52W High$13.48
52W Low$0.89

CEL-SCI Corporation (CVM) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

cvm · pe ratio · data through Sep 30, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for CEL-SCI Corporation (CVM) measures how much investors pay for each dollar of the company's trailing earnings. CVM's current PE ratio of N/A is calculated by dividing its stock price of $1.38 by its TTM earnings per share of -$2.79.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-09-30

Forward P/E
N/A
FY2026 est. EPS $-4.16
Based on 1 analyst
EPS (TTM)
-$2.79
TTM · diluted EPS
PEG Ratio
-0.00
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · CEL-SCI Corporation SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2006 – 2025 · Annual
PE Ratio (TTM)
5Y Avg 14.8x
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
CEL-SCI Corporation
CEL-SCI CorporationYou
CVM
$9MN/A-$2.79
Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc.
ALGS
$31MN/A-$2.45
Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc
BRNS
$28MN/A-$1.64
FibroGen, Inc.
FibroGen, Inc.
FGEN
$37M0.19x$45.38
INmune Bio, Inc.
INmune Bio, Inc.
INMB
$34MN/A-$1.73
Kezar Life Sciences, Inc.
Kezar Life Sciences, Inc.
KZR
$54MN/A-$7.66
Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc.
MRSN
$145MN/A-$14.12

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 20 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-09-30Latest
FY2025
$-6.27
2024-09-30
FY2024
$-13.54
2023-09-30
FY2023
$-21.83
2022-09-30
FY2022
$-26.61
2021-09-30
FY2021
$-28.91
2020-09-30
FY2020
$-26.30
2019-09-30
FY2019
$-21.74
2018-09-30
FY2018
$-1685.05
2017-09-30
FY2017
$-1638.03
2016-09-30
FY2016
$-62.78

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for CEL-SCI Corporation (CVM) measures how much investors pay for each dollar of the company's trailing earnings. CVM's current PE ratio of N/A is calculated by dividing its stock price of $1.38 by its TTM earnings per share of -$2.79.

PE Ratio = Stock Price ÷ EPS (TTM)
= $1.38 ÷ -$2.79 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

CVM pe ratio · 6 questions

CVM's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.38 and TTM EPS of -$2.79. Data sourced from Financial Modeling Prep via CVM's SEC 10-K and 10-Q filings.

CVM PE ratioWhat is CVM PE ratioCurrent PE ratio of CVMCVM PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · CEL-SCI Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09